Additionally, administration of the anti-IL-17A antibody enhanced weight loss due to CDI (Fig. S-5A) and induced the upregulation of colon pro-inflammatory markers, such as TNF-α, while IL-10 was decreased (Figs. 6C and S-5B). Here, IL17A is linked to clostridium difficile infection.